A small proportion (~20%) of multiple myeloma (MM) patients are at a high risk of relapse and aggressive disease progression. Identification of these patients can lead to more informed, individualized treatment plans to improve the standard of care in both high- and low-risk patients. In this video, recorded at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Matthew Jenner, MBBS, MRCP, FRCPath, PhD, of University Hospital Southampton NHS Foundation Trust, Southampton, UK, discusses the MUK Nine trial (NCT03188172), which has shown that screening for gene copy abnormalities, adverse gene translocations and gene expression profiling can be carried out in a short timeframe, meaning that such screening could be a practical addition to everyday clinical practice in the future. The next steps for this trial are to treat high-risk patients with a specialized and aggressive therapy in the MUK Nine b trial arm.
Genetic profiling for high-risk MM is practical in a short timeframe
